Equities analysts expect that AxoGen, Inc. (NASDAQ:AXGN) will announce ($0.11) earnings per share for the current quarter, according to Zacks. Three analysts have issued estimates for AxoGen’s earnings, with estimates ranging from ($0.15) to ($0.09). AxoGen also posted earnings of ($0.11) per share in the same quarter last year. The firm is scheduled to issue its next quarterly earnings results on Thursday, May 3rd.

According to Zacks, analysts expect that AxoGen will report full-year earnings of ($0.28) per share for the current year, with EPS estimates ranging from ($0.38) to ($0.20). For the next year, analysts expect that the company will report earnings of ($0.10) per share, with EPS estimates ranging from ($0.26) to $0.09. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover AxoGen.

AxoGen (NASDAQ:AXGN) last released its earnings results on Wednesday, February 28th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.02. AxoGen had a negative return on equity of 70.63% and a negative net margin of 17.29%. The business had revenue of $16.97 million for the quarter, compared to analyst estimates of $16.38 million. During the same quarter in the prior year, the company posted ($0.10) earnings per share. AxoGen’s revenue was up 48.7% on a year-over-year basis.

AXGN has been the topic of a number of recent research reports. Lake Street Capital set a $38.00 target price on AxoGen and gave the stock a “buy” rating in a research note on Friday, March 2nd. JMP Securities increased their target price on AxoGen from $27.00 to $34.00 and gave the stock a “market outperform” rating in a research note on Thursday, March 1st. BidaskClub upgraded AxoGen from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 23rd. William Blair initiated coverage on AxoGen in a research note on Monday, February 5th. They set an “outperform” rating on the stock. Finally, Cantor Fitzgerald set a $37.00 target price on AxoGen and gave the stock a “buy” rating in a research note on Monday, January 8th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. AxoGen presently has an average rating of “Buy” and a consensus price target of $31.71.

In related news, CFO Jamie Mark Grooms sold 10,300 shares of the stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $26.21, for a total transaction of $269,963.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold 169,407 shares of company stock worth $4,593,013 in the last three months. 9.33% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the business. Paloma Partners Management Co acquired a new stake in shares of AxoGen in the 4th quarter valued at $215,000. Guggenheim Capital LLC acquired a new stake in shares of AxoGen in the 4th quarter valued at $228,000. Valeo Financial Advisors LLC acquired a new stake in shares of AxoGen in the 3rd quarter valued at $244,000. Nationwide Fund Advisors boosted its holdings in shares of AxoGen by 5.5% in the 2nd quarter. Nationwide Fund Advisors now owns 14,874 shares of the medical equipment provider’s stock valued at $249,000 after purchasing an additional 774 shares in the last quarter. Finally, Gotham Asset Management LLC acquired a new stake in shares of AxoGen in the 4th quarter valued at $249,000. 68.01% of the stock is currently owned by hedge funds and other institutional investors.

Shares of AxoGen (NASDAQ AXGN) opened at $34.45 on Tuesday. AxoGen has a twelve month low of $9.70 and a twelve month high of $35.42. The stock has a market capitalization of $1,219.46, a PE ratio of -114.83 and a beta of 0.10. The company has a current ratio of 4.07, a quick ratio of 3.53 and a debt-to-equity ratio of 0.79.

COPYRIGHT VIOLATION NOTICE: “-$0.11 EPS Expected for AxoGen, Inc. (AXGN) This Quarter” was first posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/03/13/0-11-eps-expected-for-axogen-inc-axgn-this-quarter.html.

About AxoGen

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Get a free copy of the Zacks research report on AxoGen (AXGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.